Tandem Health has announced that, following Kinnevik leading its Series A financing, Christina Stenbeck is joining its board of directors.
Highlighting board representation in a startup usually makes very little sense, and for non-Swedes this time is likely no different.
But Christina Stenbeck is the largest shareholder in Kinnevik and the oldest daughter of Jan Stenbeck, who before his death had turned Kinnevik into the original Wallenberg/Investor challenger, many years before Sebastian Siemiatkowski stated he wanted to turn Flat Capital and his Klarna ownership into such a challenger (which I think sounds very exciting).
After a run of being one of Europe’s best venture and growth investors around 2010 (often teaming up with the Samwer brothers with major stakes in Zalando and other Rocket Internet companies), Kinnevik around 2019-2024 decided to cull its portfolio of more mature and often dividend paying companies to become a pure play growth-stage investor (becoming more like a growth fund than a traditional Swedish investmentbolag).
In practice this, unfortunately, turned Kinnevik from a Wallenberg/Investor challenger into something that looks like a publicly traded growth fund trading at significant discount to NAV (net asset value). The strategy change was not helped timing-wise by having a majority of NAV in non-public growth companies that still were/are loss making during 2022-2025.
Christina Stenbeck left the Kinnevik board in 2016 (but remained on the boards of Spotify and Zalando for several years) and rejoined the board earlier this year, which has given Kinnevik investors hope of a better future after a few years of weak stock performance.
Tandem Health is, in my opinion, one of three current frontrunners of high international quality among Swedish AI application startups and that Kinnevik both made the investment and now is putting the main person on its board is hopefully a positive sign both for Tandem Health and Kinnevik.
